Catalent Announces New Organisation to Speed New Products to Market
Catalent Pharma Solutions has announced that Sharon Johnson, Senior Vice President, Global Quality & Regulatory Affairs, is to head up Catalent’s newly formed Quality, Product Development & Regulatory Affairs organisation, established to further build upon Catalent’s leadership in new product development, regulatory excellence, reliable supply and quality.
One of the key functions of the new organisation will be to focus further on partnering with customers as part of Catalent’s New Product Introduction Excellence programme. An important factor in Catalent’s revenue and growth strategy, the programme has expanded at a rate of more than 70% over the past 3 years, from 59 new product launches globally in 2012, to 97 in 2013, and 175 in 2014.
“The overall goal of the Quality, Product Development & Regulatory Affairs organisation will be to drive excellence and reliability across all of the products that we make and deliver,” explained Johnson. “Our customer promise is not only to provide a reliable supply of their current, ongoing products, but to deliver new products with the same rigorous commitment to excellence. Bringing together these two functions into one team will tighten collaboration and the partnerships across the organisation which are needed to bring more new, innovative and life-saving products to market quicker.”
Ms Johnson will oversee a global function that includes more than 1500 scientists, quality professionals and regulatory affairs experts. Catalent’s 300 R&D scientists work across 20 global development teams to develop up to 500 new products at any one time. Catalent’s Quality and Regulatory Affairs teams have helped the company gain accreditation by over 30 global agencies, to supply more than 7000 products to in excess of 1000 customers. These products are delivered to over 80 countries, with Catalent maintaining a 100% success rate on new Pre-Approval Inspections (PAIs), and a regulatory inspections outcome rate that is two times better than the industry average.
Prior to assuming her new responsibilities, Ms Johnson had served as Catalent’s Senior Vice President, Global Quality & Regulatory Affairs since 2009, having overseen the roll-out of Catalent’s Global Quality Management system to over 20 global sites. Ms Johnson has more than 3 years of experience in the pharmaceutical industry, including API and multiple dosages forms, from discovery and launch of NCEs and life cycle management. Prior to joining Catalent, Ms Johnson served as Vice President of Quality for GE Healthcare’s Medical Diagnostic Division, having previously worked in roles of increasing responsibility for Baxter Healthcare and Sanofi Aventis.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance